Skip to main content

REVIEW article

Front. Drug Discov.
Sec. Technologies and Strategies to Enable Drug Discovery
Volume 4 - 2024 | doi: 10.3389/fddsv.2024.1474331
This article is part of the Research Topic Exploring Drug Development With Single Cell Omics Analytics and Stem Cell-Based Disease Models View all 3 articles

Single-cell multiomics: A New Frontier in Drug Research and Development

Provisionally accepted
Haiqing Xiong Haiqing Xiong 1*Jiaxiu Ma Jiaxiu Ma 1Chao Dong Chao Dong 2Aibin He Aibin He 2
  • 1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
  • 2 Institute of Molecular Medicine, Peking University, Beijing, Beijing, China

The final, formatted version of the article will be published soon.

    Single-cell multiomics (sc-multiomics) is a burgeoning field that simultaneously integrates multiple layers of molecular information, enabling the characterization of dynamic cell states and activities in development and disease as well as treatment response. Studying drug actions and responses using scmultiomics technologies has revolutionized our understanding of how small molecules intervene for specific cell types in cancer treatment and how they are linked with disease etiology and progression. Here, we summarize recent advances in sc-multiomics technologies that have been adapted and improved in drug research and development, with a focus on genome-wide examination of drugchromatin engagement and the applications in drug response and the mechanisms of drug resistance. Furthermore, we discuss how state-of-the-art technologies can be taken forward to devise innovative personalized treatment modalities in biomedical research.

    Keywords: Sc-multiomics, drug research and development, small molecule, Drug-chromatin interaction, drug response

    Received: 01 Aug 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Xiong, Ma, Dong and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Haiqing Xiong, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.